Current challenges in the management of breast cancer includes a continuous search for sensitive and specific minimally invasive biomarkers that can be exploited to detect early neoplastic changes, thus facilitating the detection of breast cancer at an early stage, as well as for monitoring the progress of patients with breast cancer and their response to treatments. This study investigated the expression pattern of miR-16, 21, 145, and 375 in plasma of breast cancer patients at different clinical stages of the disease. Informed consents were obtained from forty-nine (49) participants diagnosed with breast cancer and receiving chemotherapy treatment at the Lagos University Teaching Hospital (LUTH) and twenty-seven (27) healthy individuals. miRNA was isolated from plasma, reversed transcribed and quantified using SYBR green chemistry semi-quantitative PCR. Cases comprised of 2(5.6%) stage-I, 13(36.1%) stage-II, 12(33.3%) stage-III patients, and 9(25.0%) Stage IV patients. The was a non-significant increase in miRNA-16 and 21 expression levels in BC compared with the control group; miRNA-145 was non-significantly downregulated as the disease progressed from stage II to IV; while there was no observable difference between BC cases and the control group. The data suggests the possible use of miRNA 16, 21, 145, and 375 expression levels as diagnostic and prognostic markers in breast cancer management.